Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ettore Dolcetti

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Frontiers in Neurology|February 24, 2022
Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple SclerosisAntonio Bruno, Ettore Dolcetti, Diego Centonze
Neural Regeneration Research|December 16, 2023
Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosisFederica Azzolini, Ettore Dolcetti, Antonio Bruno, et al.
Multiple Sclerosis and Related Disorders|May 14, 2021
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumabFabio Buttari, Antonio Bruno, Ettore Dolcetti, et al.
Frontiers in Molecular Neuroscience|December 6, 2018
Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and DepressionMario Stampanoni Bassi, Luana Gilio, Pierpaolo Maffei, et al.
Neurobiology of Disease|August 1, 2017
Interferon-γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatumGeorgia Mandolesi, Silvia Bullitta, Diego Fresegna, et al.
Therapeutic Advances in Neurological Disorders|June 23, 2025
Cladribine tablets in the new multiple sclerosis eraFabio Buttari, Ettore Dolcetti, Francesca Romana Rizzo, et al.
Neurology and Therapy|April 22, 2025
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled TrialsBledar Gjikolaj, Mario Stampanoni Bassi, Antonio Bruno, et al.
Current Neuropharmacology|September 16, 2024
Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple SclerosisAntonio Bruno, Pietro Annovazzi, Marinella Clerico, et al.
Current Neuropharmacology|September 24, 2024
Disease-Modifying Symptomatic Treatment (DMST): The Potential Role of Vortioxetine in the Treatment of Depression in Patients with Multiple SclerosisEttore Dolcetti, Pietro Annovazzi, Marinella Clerico, et al.
Frontiers in Psychiatry|July 15, 2025
Investigating depression in multiple sclerosis: an Italian Delphi consensus on clinical manifestations, diagnosis and treatmentAntonio Bruno, Ettore Dolcetti, Pietro Annovazzi, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Frontiers in Neurology|February 24, 2022
Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple SclerosisAntonio Bruno, Ettore Dolcetti, Diego Centonze
Neural Regeneration Research|December 16, 2023
Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosisFederica Azzolini, Ettore Dolcetti, Antonio Bruno, et al.
Multiple Sclerosis and Related Disorders|May 14, 2021
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumabFabio Buttari, Antonio Bruno, Ettore Dolcetti, et al.
Frontiers in Molecular Neuroscience|December 6, 2018
Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and DepressionMario Stampanoni Bassi, Luana Gilio, Pierpaolo Maffei, et al.
Neurobiology of Disease|August 1, 2017
Interferon-γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatumGeorgia Mandolesi, Silvia Bullitta, Diego Fresegna, et al.
Therapeutic Advances in Neurological Disorders|June 23, 2025
Cladribine tablets in the new multiple sclerosis eraFabio Buttari, Ettore Dolcetti, Francesca Romana Rizzo, et al.
Neurology and Therapy|April 22, 2025
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled TrialsBledar Gjikolaj, Mario Stampanoni Bassi, Antonio Bruno, et al.
Current Neuropharmacology|September 16, 2024
Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple SclerosisAntonio Bruno, Pietro Annovazzi, Marinella Clerico, et al.
Current Neuropharmacology|September 24, 2024
Disease-Modifying Symptomatic Treatment (DMST): The Potential Role of Vortioxetine in the Treatment of Depression in Patients with Multiple SclerosisEttore Dolcetti, Pietro Annovazzi, Marinella Clerico, et al.
Frontiers in Psychiatry|July 15, 2025
Investigating depression in multiple sclerosis: an Italian Delphi consensus on clinical manifestations, diagnosis and treatmentAntonio Bruno, Ettore Dolcetti, Pietro Annovazzi, et al.
Pageof 5